期刊
PIGMENT CELL & MELANOMA RESEARCH
卷 22, 期 6, 页码 785-798出版社
WILEY
DOI: 10.1111/j.1755-148X.2009.00618.x
关键词
BRAF; MEK; kinase inhibitor; melanoma; microarray
资金
- National Health and Medical Research Council of Australia
- Harry J Lloyd Charitable Trust
- Cancer Research UK [C107/A3096, C107/A10433]
- The Institute of Cancer Research
- Breakthrough Breast cancer
- NIHR Biomedical Research Centre
P>Oncogenic mutations in BRAF are common in melanoma and drive constitutive activation of the MEK/ERK pathway. To elucidate the transcriptional events downstream of V600EBRAF/MEK signalling we performed gene expression profiling of A375 melanoma cells treated with potent and selective inhibitors of V600EBRAF and MEK (PLX4720 and PD184352 respectively). Using a stringent Bayesian approach, we identified 69 transcripts that appear to be direct transcriptional targets of this pathway and whose expression changed after 6 h of pathway inhibition. We also identified several additional genes whose expression changed after 24 h of pathway inhibition and which are likely to be indirect transcriptional targets of the pathway. Several of these were confirmed by demonstrating their expression to be similarly regulated when BRAF was depleted using RNA interference, and by using qRT-PCR in other BRAF mutated melanoma lines. Many of these genes are transcription factors and feedback inhibitors of the ERK pathway and are also regulated by MEK signalling in NRAS mutant cells. This study provides a basis for understanding the molecular processes that are regulated by V600EBRAF/MEK signalling in melanoma cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据